

**UNITED STATES BANKRUPTCY COURT
FOR THE WESTERN DISTRICT OF THE STATE OF OKLAHOMA**

IN RE:)
) Case No. 06-12867
 Moore Medical Center, LLC) Chapter 7
)
 DEBTOR)

2013 SEP 27 P 4:04

COURT OF APPEALS OF THE UNITED STATES OF AMERICA
WESTERN DISTRICT OF OKLAHOMA
RECEIVED

**APPLICATION FOR ORDER DIRECTING PAYMENT
OF FUNDS TO CREDITOR/CLAIMANT PURSUANT TO
11 U.S.C. SECTION 347 AND 28 U.S.C SECTIONS 2041 ET. SEQ.**

Dilks & Knopik, LLC, Attorney-in-Fact for Baxter International Inc. (the "Claimant") a claimant for the captioned case respectfully requests as follows:

1. Baxter Healthcare was a creditor of the Debtor and was due to receive and the trustee did, in fact, make a distribution from the estate to Baxter Healthcare in the amount of approximately \$4,792.59. Baxter Healthcare was not located and the funds of the creditor were paid into the Court pursuant to 11 U.S.C. Section 347.
2. Pursuant to 11 U.S.C. Section 347 and chapter 129 of title 28, United States Code, the claimant requests that the Court issue an order directing payment to the creditor and the claimant and that payment be made in care of Baxter International Inc. and Dilks & Knopik, LLC, 35308 SE Center St, Snoqualmie, WA 98065.

WHEREFORE, Claimant requests that the Court issue an order directing payment of all funds held by the Court in this case and for such further and other relief as is just and appropriate. The U.S. Attorney for the Western District of Oklahoma has been noticed with a true and correct copy of this application.

Date: July 16, 2013

By:

Brian J. Dilks, Managing Member
Dilks & Knopik, LLC, Attorney in Fact for
Baxter International Inc.

STATE OF WASHINGTON, COUNTY OF KING

On 7/16/2013 before me, personally appeared Brian J. Dilks personally known to me (or proved to me on the basis of satisfactory evidence) to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument. WITNESS my had and official seal.



Andrew T. Drake, Notary Public
My commission expires on August 9, 2015

(SEAL)



**UNITED STATES BANKRUPTCY COURT
FOR THE WESTERN DISTRICT OF THE STATE OF OKLAHOMA**

IN RE:)
Moore Medical Center, LLC) Case No. 06-12867
DEBTOR) Chapter 7

)

CASE HISTORY:

The original dividend check was sent to a Baxter Healthcare. Baxter Healthcare is fully known as Baxter Healthcare Corporation. Baxter Healthcare Corporation is a wholly owned subsidiary of Baxter International, Inc., as evidenced by Exhibit A.

UNITED STATES BANKRUPTCY COURT
WESTERN DISTRICT OF OKLAHOMA

)
RE: Moore Medical Center, LLC)
)
)
)
Debtor(s))

Case: 06-12867

AUTHORITY TO ACT
Limited Power of Attorney
Limited to one Transaction

USED ONLY TO COLLECT FUNDS FROM THE ABOVE REFERENCED CASE

1. Baxter International Inc. with a tax identification number of 36-0781620, ("CLIENT"), appoints Dilks & Knopik, LLC ("D&K"), as its lawful attorney in fact for the limited purpose of recovering, receiving and obtaining information pertaining to the outstanding tender of funds in the amount of \$4,792.59 (the "FUNDS"), including the right to collect on CLIENT's behalf any such funds that are held by a governmental agency or authority.
2. CLIENT grants to D&K the authority to do all things legally permissible and reasonably necessary to recover or obtain the FUNDS held by the governmental agency or authority. This limited authority includes the right to receive all communications from the governmental agency or authority and to deposit checks payable to CLIENT for distribution of the FUNDS to CLIENT, less the fee payable to D&K pursuant to and in accordance with its agreement with CLIENT.
3. D&K may not make any expenditure or incur any costs or fees on behalf of CLIENT without CLIENT's prior written consent.
4. This Authority to Act shall become effective on the below signed date and shall expire upon collection of the aforementioned FUNDS. I authorize the use of a photocopy of this Limited Power of Attorney in lieu of the original.

Shawn M. Ryan
Shawn M. Ryan - Credit Manager *Taylor L. Jones*

Date

7/8, 2013

Baxter

Shawn Ryan
Manager II, Operations

Baxter Healthcare Corporation
25212 W. IL Route 120
Round Lake, Illinois 60073
T 224.270.1238 F 224.270.3311 F 877.294.7784
shawn_ryan@baxter.com

ACKNOWLEDGMENT

STATE OF ILLINOIS)

COUNTY OF LAKE)

On this 8th day of July, 2013, before me, the undersigned Notary Public in and for the said County and State, personally appeared (name) Shawn M. Ryan known to me to be the person described in and who executed the foregoing instrument, and who acknowledged to me that (circle one) he/she did so freely and voluntarily and for the uses and purposes therein mentioned.

WITNESS my hand and official seal.

NOTARY PUBLIC

Shawn M. Gustafson
Residing at Baxter Healthcare, Round Lake, IL

My Commission expires 3/1/14





UNITED STATES BANKRUPTCY COURT
FOR THE WESTERN DISTRICT OF OKLAHOMA

In Re: _____)
Moore Medical Center, LLC) Case: 06-12867
Debtor(s) _____) Chapter:

_____)

AFFIDAVIT OF CREDITOR

State of ILLINOIS)

County of LAKE)

I, Shawn M. Ryan, Credit Manager of Baxter International Inc., the undersigned creditor in the above referenced case, being first duly sworn upon oath, state as follows:

1. Dilks & Knopik, LLC, 35308 SE Center Street, Snoqualmie, WA 98065 has been granted a power of attorney by me to submit an Application for Payment from Unclaimed Funds seeking payment of claim no. in the amount of \$4,792.59 due and owing to me (or the company I represent) as a creditor in the above referenced bankruptcy case.

2. My name, address and telephone number are as follows:


Baxter International Inc.
Shawn M. Ryan, Credit Manager
25212 W. IL Rte 120 WG1-2S
Round Lake, IL 60073
224.948.2000

3. Substantiate creditor's right to claim, including but not limited to documents relating to sale of company, i.e. purchase agreements and/or stipulation by prior and new owner as to right of ownership of funds. Attach certified copies of all necessary documentation.

4. I (or the entity I represent) have neither previously received remittance for the claim nor have contracted with any other party than the person named in item one above to recover these funds.


I hereby certify that the foregoing statements are true and correct to the best of my knowledge and belief.

Dated: 7/8/2013



Shawn M. Ryan

Subscribed and sworn to before me this 8th day of July, 20 13.


Notary Public

(SEAL)
My commission Expires:

3/1/14



Table of Contents

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-K

(Mark One)

- ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**
For the fiscal year ended December 31, 2012
- OR
- TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**
For the transition period from _____ to _____
- Commission file number 1-4448

Baxter
Baxter International Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware

*(State or Other Jurisdiction of
Incorporation or Organization)*

One Baxter Parkway, Deerfield, Illinois
(Address of Principal Executive Offices)

36-0781620

(I.R.S. Employer Identification No.)

60015

(Zip Code)

Registrant's telephone number, including area code 224.948.2000

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Common stock, \$1.00 par value

Name of Each Exchange on Which Registered

New York Stock Exchange

Chicago Stock Exchange

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes No

The aggregate market value of the voting common equity held by non-affiliates of the registrant as of June 29, 2012 (the last business day of the registrant's most recently completed second fiscal quarter), based on the per share closing sale price of \$53.15 on that date and the assumption for the purpose of this computation only that all of the registrant's directors and executive officers are affiliates, was approximately \$29 billion. There is no non-voting common equity held by non-affiliates of the registrant.

The number of shares of the registrant's common stock, \$1.00 par value, outstanding as of January 31, 2013 was 545,928,648.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the registrant's definitive 2013 proxy statement for use in connection with its Annual Meeting of Shareholders to be held on May 7, 2013 are incorporated by reference into Part III of this report.

Exhibit A

EXHIBIT 21**Subsidiaries of Baxter International Inc.**

<u>Subsidiary</u>	<u>Organized under laws of</u>	<u>% owned by immediate parent(1)</u>
Baxter International Inc.	Delaware	100
Baxter Colorado Holding Inc.	Colorado	100
Baxa Corporation	Colorado	100
Baxter Healthcare Corporation	Delaware	100
Baxter Pharmaceutical Solutions LLC	Delaware	100
BioLife Plasma Services L.P.	Pennsylvania	99(2)
Baxter Holding Services Company	Minnesota	100
Symovis Life Technologies, Inc.	Delaware	100
Baxter World Trade Corporation	Canada	100
Baxter Corporation	Venezuela	100
Baxter de Venezuela, C.A.	Nevada	100
Baxter Export Corporation	Delaware	100
Baxter Global Holdings Inc.	Australia	99.99(2)
Baxter Healthcare Pty Ltd	Taiwan	100
Baxter Healthcare Limited	Mexico	99.99(2)
Baxter Holding Mexico, S. de R.L. de C.V.	Mexico	99.99(2)
Baxter S.A. de C.V.	Japan	100
Baxter Holdings Limited	Japan	100
Baxter Limited	Delaware	100(3)
Baxter Sales and Distribution Corp.	Alaska	100
Baxter Healthcare Corporation of Puerto Rico	Delaware	100
Baxter Global Holdings II Inc.	The Netherlands	100
Baxter Holding B.V.	United Kingdom	100
ApTech Limited	Switzerland	100
Baxter AG	Argentina	93.08(2)
Baxter Argentina S.A.	United Kingdom	100
Baxter Healthcare (Holdings) Limited	United Kingdom	100
Baxter Healthcare Limited	Greece	99.8(2)
Baxter (Hellas) EPE	Switzerland	100
Baxter Healthcare Holding GmbH	Switzerland	100
Baxter Healthcare SA	United Kingdom	100
Baxter Healthcare Pharmaceutical Limited	Singapore	100
Baxter Pacific Investments Pte Ltd	China	100
Baxter (China) Investment Co., Ltd.	China	87.5
Baxter Healthcare (Guangzhou) Company Ltd	China	100
Baxter Healthcare (Suzhou) Company Ltd.	China	100
Baxter Healthcare (Shanghai) Company Ltd	India	99.99(2)
Baxter (India) Private Limited	China	100
Baxter Healthcare Trading (Shanghai) Company Ltd.	Costa Rica	100
Baxter Productos Medicos LTDA	Switzerland	100
Baxter Trading GmbH	Switzerland	100
Baxter BioScience Manufacturing Sarl	Austria	100
Baxter Innovations GmbH	Austria	100
Baxter AG	Brazil	99.99(2)
Baxter Hospitalar Ltda.	Republic of Korea	100
Baxter Incorporated	The Netherlands	100
Baxter Netherlands Holding B.V.	Belgium	99.97(2)
Baxter S.A.	Turkey	49.99(4)
Ezazibasi-Baxter Hastane Unnleri Sanayi ve Ticaret A.S.	Germany	94(2)
Baxter Deutschland Holding GmbH	Germany	100
Baxter Deutschland GmbH	Germany	100
Baxter Oncology GmbH	Belgium	99.99(2)
Baxter World Trade SPRL	Italy	100
Baxter World Trade Italy S.R.L.	Italy	98.98(2)
Baxter S.p.A.	Italy	98.98(2)
Baxter Manufacturing S.p.A.	Italy	99.46
Bieffe Medical S.p.A.	The Netherlands	100
Bieffe Medital Nederland NV	Switzerland	100
Sapa Prodotti Plastici Sagl	Delaware	100
Laboratorios Baxter S.A.	Delaware	100
RTS Worldwide Holdings Inc.	Colombia	99.51(2)
RTS Americas Inc.	Colombia	100
RTS Colombia Ltda.	Colombia	100
RTS S A S		

Subsidiaries omitted from this list, considered in aggregate as a single subsidiary, would not constitute a significant subsidiary. All subsidiaries set forth herein are reported in the Company's financial statements through consolidation or under the equity method of accounting.

- (1) Including nominee shares.
- (2) Remaining shares owned by the Company, or other subsidiaries of the Company.
- (3) Of common stock, with preferred stock held by Baxter Healthcare Corporation.
- (4) Baxter's total ownership in this joint venture is 50%. The remaining .001% is owned by other Baxter entities.

Exhibit**A**